July 6, 2016
On July 5, 2016 Bristol-Myers Squibb (BMS) announced that it has acquired Cormorant Pharmaceuticals, a private Swedish pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition will give BMS full rights to Cormorant’s HuMax-IL8 antibody program, including the lead candidate HuMax-IL8, a monoclonal antibody targeted against interleukin-8 (IL-8) that represents a potentially complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules. Cormorant acquired the rights to HuMax-IL8 from Genmab A/S in 2012 under an exclusive license agreement, BMS said in a press announcement.
The transaction includes an upfront and near term continent milestone payments of up to $95 million and additional continent considerations of up to $425 million upon BMS achieving certain regulatory milestones. The transaction has been approved by the boards of directors of both companies and by the stockholders of Cormorant.
Source: Bristol-Myers Squibb
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.